Stock Events

Stock Events

ETHZilla 

$0.01
110
-$0.02-71.96% Wednesday 21:00

Statistics

Day High
0.03
Day Low
0.01
52W High
0.03
52W Low
0.01
Volume
1,191,169
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25FebExpected
Q2 2024
Q2 2025
Q3 2025
Q4 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.18MNet Income

Analyst Ratings

$5.00Average Price Target
The highest estimate is 5.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ETHZW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

ETHZilla operates in digital asset management, gaming, and entertainment. The Company is developing an Ether (ETH) accumulation vehicle to serve as a benchmark for on-chain treasury management among public companies, supported by Electric Capital and a DeFi Council of industry experts. Its strategy targets yield generation beyond traditional ETH staking while advancing gaming initiatives and pursuing monetization of legacy biotechnology assets from its origins as a biotech company.
Show more...
CEO
Mr. McAndrew Rudisill BA(Econ)
Employees
4
Country
US

Listings

F
DE
L270.F
BOATS
BOATS
ETHZ.BOATS
XNAS
US
FRMM

0 Comments

Share your thoughts

FAQ

What is ETHZilla stock price today?▼
The current price of ETHZW is $0.01 USD — it has decreased by -71.96% in the past 24 hours. Watch ETHZilla stock price performance more closely on the chart.
What is ETHZilla stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ETHZilla stocks are traded under the ticker ETHZW.
What is ETHZilla revenue for the last year?▼
ETHZilla revenue for the last year amounts to 0 USD.
What is ETHZilla net income for the last year?▼
ETHZW net income for the last year is -14.18M USD.
How many employees does ETHZilla have?▼
As of April 10, 2026, the company has 4 employees.
When did ETHZilla complete a stock split?▼
ETHZilla has not had any recent stock splits.
Where is ETHZilla headquartered?▼
ETHZilla is headquartered in Palm Beach, US.